Magritek opens up benchtop NMR to new reaction monitoring applications

CD Formulation's Scientists Share A Holistic Approach on How to Prepare Drug Microcapsules

Cresset Targets International Growth with Innovate UK Scaleup Programme

Drug discovery specialists Cresset have joined Innovate UK’s Scaleup Programme for businesses with high growth potential

New £30m Initiative to Address Global Threat by Accelerating the Pace of Antimicrobial Innovation

Pioneering partnership to drive development of new tests and treatments to tackle deadly antimicrobial resistance, which could otherwise kill 10 million a year by 2050

CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

CD Genomics Unveils Cutting-Edge CRISPR Screen Sequencing Technology

BOC Sciences at TIDES Europe 2023: Key Chemicals and XDC Platform to Be Exhibited

BOC Sciences will attend "TIDES Europe: Oligonucleotide & Peptide Therapeutics", delivered as a hybrid event from 30 Oct - 1 Nov 2023, in Amsterdam, NL. Its high-yield nucleosides & nucleotides, as well as a newly launched XDC platform, will be exhibited in front of the industry.

CD Genomics Introduces Cutting-Edge Degradome Sequencing Service Redefining Transcriptomics Research

Biotium Introduces New Highly-Selective Stains For Both Gram-Positive and Gram-Negative Bacteria

Biotium has announced the launch of its breakthrough BactoView™ Dead Stains and BactoView™ Viability Kits.

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.

Inizio Engage launches new global powerhouse learning brand, Nazaré

Censinet and First Health Advisory Partner to Deliver Comprehensive Cyber Risk Assurance to Health Sector

Partnership Enables Healthcare Organizations to Leverage Unique Risk Advisory Services and Purpose-Built Workflow Automation to Maximize Cyber Risk Reduction

JPA HEALTH EXPANDS LIFE SCIENCES DIVISION WITH ACQUISITION OF TRUE NORTH SOLUTIONS, INC.

Addition brings together synchronized experts to offer comprehensive predictive analytics, data visualization and AI-driven end-to-end solutions for life sciences, government and non-profit organizations

Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics

Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics. The multi-year agreement will use Owkin’s sophisticated AI to potentially enable Servier to develop novel therapeutics across various disease areas.

Expanding Research Horizons: CD Formulation Unveils its Redesigned Collection of Pharmaceutical Excipients

Unleashing Diamond's Full Potential: Alfa Chemistry's Single Crystalline and Polycrystalline Diamond Transformations

Discovery Park and Researcher partner to support scientific collaboration

Discovery Park, Kent’s thriving life science community, has partnered with scientific content discovery and discussion platform, Researcher, to promote collaboration and facilitate scientific progress.

ISPE Names Genentech the 2023 Facility of the Year Awards Overall Winner

ISPE has recognized Genentech as the 2023 Facility of the Year Awards (FOYA) Overall Winner for the Clinical Supply Center (CSC) project located in South San Francisco, California, USA.

OncoDxRx Showcases Advanced Applications of One-Of-A-Kind PGA Test in Taiwan

When cfDNA testing result is negative or patients become unresponsive/resistant to current existing treatment strategy, plasma-based cfmRNA testing (ie., OncoDxRx’s PGA assay) can help clinicians to select the most effective therapy available within 5 days. Particularly in advanced cases of cancer, wait times associated with complex NGS testing of cfDNA can significantly impact a patient’s time to treatment and overall outcome.